157 related articles for article (PubMed ID: 18221035)
1. Thymidine phosphorylase (platelet-derived endothelial cell growth factor) as a target for capecitabine: from biology to the bedside.
Ranieri G; Roccaro AM; Vacca A; Ribatti D
Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):171-83. PubMed ID: 18221035
[TBL] [Abstract][Full Text] [Related]
2. Thymidine phosphorylase (TP) activation: convenience through innovation.
Van Cutsem E; Cunningham D; Hoff PM; Maroun J
Oncologist; 2001; 6 Suppl 4():1-2. PubMed ID: 11585967
[No Abstract] [Full Text] [Related]
3. Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story.
Ciccolini J; Evrard A; Cuq P
Curr Med Chem Anticancer Agents; 2004 Mar; 4(2):71-81. PubMed ID: 15032715
[TBL] [Abstract][Full Text] [Related]
4. Thymidine phosphorylase profiles in nonmalignant and malignant pancreatic tissue. Potential therapeutic role of capecitabine on tumoral and endothelial cells and tumor-infiltrating macrophages.
Passantino L; Patruno R; Valerio P; Penna A; Mazzone F; Zito AF; Catalano V; Pellecchia A; Jirillo E; Ranieri G
Immunopharmacol Immunotoxicol; 2005; 27(1):95-107. PubMed ID: 15803863
[TBL] [Abstract][Full Text] [Related]
5. Making capecitabine targeted therapy for breast cancer: which is the role of thymidine phosphorylase?
Bonotto M; Bozza C; Di Loreto C; Osa EO; Poletto E; Puglisi F
Clin Breast Cancer; 2013 Jun; 13(3):167-72. PubMed ID: 23218471
[TBL] [Abstract][Full Text] [Related]
6. The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
Temmink OH; Prins HJ; van Gelderop E; Peters GJ
Br J Cancer; 2007 Jan; 96(1):61-6. PubMed ID: 17179993
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy.
Chung YL; Troy H; Judson IR; Leek R; Leach MO; Stubbs M; Harris AL; Griffiths JR
Clin Cancer Res; 2004 Jun; 10(11):3863-70. PubMed ID: 15173095
[TBL] [Abstract][Full Text] [Related]
8. [Improved sensitivity of gastric carcinoma cells to fluorouracil-related drugs by transfection of thymidine phosphorylase gene].
Zhuo LJ; Gao MQ; Huang AM
Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):330-3. PubMed ID: 21756828
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase.
Saif MW; Black G; Roy S; Bell D; Russo S; Eloubeidi MA; Steg A; Johnson MR; Zelterman D; Diasio RB
Cancer J; 2007; 13(4):247-56. PubMed ID: 17762760
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.
Morita T; Matsuzaki A; Tokue A
Int J Cancer; 2001 May; 92(3):451-6. PubMed ID: 11291085
[TBL] [Abstract][Full Text] [Related]
11. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy.
Nishimura G; Terada I; Kobayashi T; Ninomiya I; Kitagawa H; Fushida S; Fujimura T; Kayahara M; Shimizu K; Ohta T; Miwa K
Oncol Rep; 2002; 9(3):479-82. PubMed ID: 11956613
[TBL] [Abstract][Full Text] [Related]
12. Targeting platelet-derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy.
Liekens S; Bronckaers A; Pérez-Pérez MJ; Balzarini J
Biochem Pharmacol; 2007 Dec; 74(11):1555-67. PubMed ID: 17572389
[TBL] [Abstract][Full Text] [Related]
13. Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes.
Yasuno H; Kurasawa M; Yanagisawa M; Sato Y; Harada N; Mori K
Oncol Rep; 2013 Feb; 29(2):451-8. PubMed ID: 23229803
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological and clinical properties of Xeloda (Capecitabine), a new oral active derivative of fluoropyrimidine].
Nishida M
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):549-53. PubMed ID: 14639009
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
Aprile G; Mazzer M; Moroso S; Puglisi F
Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
[TBL] [Abstract][Full Text] [Related]
16. An epigenetic mechanism for capecitabine resistance in mesothelioma.
Kosuri KV; Wu X; Wang L; Villalona-Calero MA; Otterson GA
Biochem Biophys Res Commun; 2010 Jan; 391(3):1465-70. PubMed ID: 20035722
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer.
Saeki T; Takashima S
Breast Cancer; 2004; 11(2):116-20. PubMed ID: 15550855
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice.
Xiao YS; Tang ZY; Fan J; Zhou J; Wu ZQ; Sun QM; Xue Q; Zhao Y; Liu YK; Ye SL
J Cancer Res Clin Oncol; 2004 Sep; 130(9):546-50. PubMed ID: 15071737
[TBL] [Abstract][Full Text] [Related]
19. Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.
Di Gennaro E; Piro G; Chianese MI; Franco R; Di Cintio A; Moccia T; Luciano A; de Ruggiero I; Bruzzese F; Avallone A; Arra C; Budillon A
Br J Cancer; 2010 Nov; 103(11):1680-91. PubMed ID: 21045833
[TBL] [Abstract][Full Text] [Related]
20. The rational development of capecitabine from the laboratory to the clinic.
Pentheroudakis G; Twelves C
Anticancer Res; 2002; 22(6B):3589-96. PubMed ID: 12552961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
